



# Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

9<sup>th</sup> August 2022

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
**Mumbai – 400 001.**

The Manager – Listing  
M/s. National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra-Kurla Complex  
Bandra(E), **MUMBAI – 400 051.**

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

## **Sub: Outcome of Board Meeting**

We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business:

1. On the basis of the recommendations of Nomination & Remuneration Committee in its meeting held today, the Board of Directors have co-opted Dr. Pavan Ganapati Bhat (DIN: 09691260) as an Additional Director and appointed him as an Executive Director i.e., Director & Executive Vice President (Technical Operations) of the Company for a period of 2 (two) years w.e.f. 9<sup>th</sup> August, 2022 subject to approval of the members of the Company at the ensuing Annual General Meeting.

Brief Profile of Dr. Pavan Ganapati Bhat, in terms of the SEBI Listing Regulations, is annexed herewith as Annexure – 1.

We hereby confirm that Dr. Pavan Ganapati Bhat is not debarred from holding the office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such authority.

2. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30<sup>th</sup> June 2022 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time ("Listing Regulations") along with Review Report of the Statutory Auditors.

Please find enclosed herewith the copy of the same for your information.

3. Declared interim dividend of Rs.3.50 (Rupees Three Rupees fifty paise only (175%) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2022-23. The date for taking on record of its shareholders eligible for the purpose of payment of interim dividend i.e., record date is fixed as **Monday the 22<sup>nd</sup> day of August, 2022.** The payment of said interim dividend will be paid from 30<sup>th</sup> August 2022.





## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, [www.natcopharma.co.in](http://www.natcopharma.co.in)

4. Revised Notice of the 39<sup>th</sup> Annual General Meeting was approved and the Board had authorised Sri V.C. Nannapaneni, Managing Director for finalizing the date, time, venue, book closure dates and mode of conducting of Annual General Meeting for the financial year 2021-22.

A Copy of Press release is also enclosed for your information.


Kindly note that the aforesaid disclosure(s) is being uploaded on the Company's website at [www.natcopharma.co.in](http://www.natcopharma.co.in), in compliance with the SEBI Listing Regulations.

Meeting commenced at 12.15 p.m. and concluded at 1.40 p.m.

Thanking you

Yours faithfully,  
For NATCO Pharma Limited

  
Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer



Encl: As above



# Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

## Annexure-1

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015

### Brief Profile of Dr. Pavan Ganapati Bhat

Sl. No.	Particulars	Remarks
1	Reason of Change	Co-opted as an Additional Director and appointed as an Executive Director i.e., Director & Executive Vice President (Technical Operations)
2	Date of Appointment	For a period of 2 (two) years w.e.f. 9 <sup>th</sup> August, 2022 subject to approval of the members of the Company at the ensuing Annual General Meeting
3	Brief Profile	<p>Dr. Pavan Ganapati Bhat (Dr. Pavan Bhat) is working as Executive Vice President (Technical Operations) of the Company. He has over 25+ years of experience in the Pharmaceutical Industry and has been working with our Company for past 6 years. He is in-charge of various departments like R&amp;D, Regulatory Affairs for Generics, NDDS and NCEs, Intellectual Property Rights of Formulations and Acquisitions.</p> <p>Dr. Pavan Bhat started his career with Mylan in USA in Transdermal R&amp;D followed by OSD R&amp;D and in Corporate &amp; Business Development. As part of the Office of the CEO, he was a key member of the acquisition team of Matrix by Mylan followed by being a part of the Integration team. He then relocated to Mylan India where he Headed Mylan's Global External R&amp;D and Regional Business Development. Finally, he was the Head of Regional Operations responsible for Portfolio Selection, Project Management, Supply Chain Management, Launch Management, Logistics and Special Projects and supporting a P&amp;L of \$ 1.2 Billion.</p>
4	Disclosure of relationships between Directors	Not related to any Director of the Company

